Tumor-induced suppression of CTL expansion and subjugation by gp96-lg vaccination

Taylor H. Schreiber, Vadim V. Deyev, Joseph D Rosenblatt, Eckhard R. Podack

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Established tumors suppress antitumor immune responses and induce tolerance by incompletely characterized mechanisms, and this phenomenon is an important barrier to tumor immunotherapy. Single vaccination with tumor cells expressing gp96-Ig stimulates robust expansion of tumor-specific CTLs in tumor-naive mice and this expansion is inhibited by established tumors. Interestingly, frequent vaccinations restore antitumor immune responses in the presence of established tumors. Syngeneic EG7 tumor-bearing mice have heterogeneous responses to frequent vaccination with EG7-gp96-Ig, with 32% complete responders and 68% partial responders. Comparison of responders to nonresponders revealed aninverse correlation between tumor-specific CTL expansion in the peripheral blood and tumor size. To identify immune cells and molecules associated with effective anti-tumor immune responses, reverse transcription-PCR arrays were performed using cells isolated from the vaccination site. ELISAs, cellular phenotyping, and tumor immunohistochemistry were also performed comparing vaccine responders to nonresponders. These data show that up-regulation of T-bet, ROHyt, IFNY, CCL8> CXCL9, and CXCLlO at the vaccination site are associated with vaccine-induced antitumor immunity. These data correlate with increased CTL expansion in the peripheral blood of responders, increased infiltration of responder tumors by CD8+ cells and interleukin-17+ cells, and decreased infiltration of responder tumors by CDllb+Gr-1+ cells and FoxP3+ cells. Furthermore, serum ELISAs revealed a significant elevation of transforming growth factor-ß in nonresponders as compared with responders. Interestingly, CD8+ T cells isolated from responders and nonresponders have equivalent cytotoxic activity in vitro. Taken together, our data suggest that established tumors may escape immuno-surveillance by preventing clonal expansion of tumor-specific CTL without inducing anergy.

Original languageEnglish
Pages (from-to)2026-2033
Number of pages8
JournalCancer Research
Volume69
Issue number5
DOIs
StatePublished - Mar 1 2009

Fingerprint

Vaccination
Neoplasms
Vaccines
Enzyme-Linked Immunosorbent Assay
Tumor Escape
Interleukin-17
Transforming Growth Factors
Immunotherapy
Reverse Transcription
Immunity
Up-Regulation
Immunohistochemistry
T-Lymphocytes
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor-induced suppression of CTL expansion and subjugation by gp96-lg vaccination. / Schreiber, Taylor H.; Deyev, Vadim V.; Rosenblatt, Joseph D; Podack, Eckhard R.

In: Cancer Research, Vol. 69, No. 5, 01.03.2009, p. 2026-2033.

Research output: Contribution to journalArticle

Schreiber, Taylor H. ; Deyev, Vadim V. ; Rosenblatt, Joseph D ; Podack, Eckhard R. / Tumor-induced suppression of CTL expansion and subjugation by gp96-lg vaccination. In: Cancer Research. 2009 ; Vol. 69, No. 5. pp. 2026-2033.
@article{e72626f7c7b7462fb3a19f75b2ff1731,
title = "Tumor-induced suppression of CTL expansion and subjugation by gp96-lg vaccination",
abstract = "Established tumors suppress antitumor immune responses and induce tolerance by incompletely characterized mechanisms, and this phenomenon is an important barrier to tumor immunotherapy. Single vaccination with tumor cells expressing gp96-Ig stimulates robust expansion of tumor-specific CTLs in tumor-naive mice and this expansion is inhibited by established tumors. Interestingly, frequent vaccinations restore antitumor immune responses in the presence of established tumors. Syngeneic EG7 tumor-bearing mice have heterogeneous responses to frequent vaccination with EG7-gp96-Ig, with 32{\%} complete responders and 68{\%} partial responders. Comparison of responders to nonresponders revealed aninverse correlation between tumor-specific CTL expansion in the peripheral blood and tumor size. To identify immune cells and molecules associated with effective anti-tumor immune responses, reverse transcription-PCR arrays were performed using cells isolated from the vaccination site. ELISAs, cellular phenotyping, and tumor immunohistochemistry were also performed comparing vaccine responders to nonresponders. These data show that up-regulation of T-bet, ROHyt, IFNY, CCL8> CXCL9, and CXCLlO at the vaccination site are associated with vaccine-induced antitumor immunity. These data correlate with increased CTL expansion in the peripheral blood of responders, increased infiltration of responder tumors by CD8+ cells and interleukin-17+ cells, and decreased infiltration of responder tumors by CDllb+Gr-1+ cells and FoxP3+ cells. Furthermore, serum ELISAs revealed a significant elevation of transforming growth factor-{\ss} in nonresponders as compared with responders. Interestingly, CD8+ T cells isolated from responders and nonresponders have equivalent cytotoxic activity in vitro. Taken together, our data suggest that established tumors may escape immuno-surveillance by preventing clonal expansion of tumor-specific CTL without inducing anergy.",
author = "Schreiber, {Taylor H.} and Deyev, {Vadim V.} and Rosenblatt, {Joseph D} and Podack, {Eckhard R.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-08-3706",
language = "English",
volume = "69",
pages = "2026--2033",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Tumor-induced suppression of CTL expansion and subjugation by gp96-lg vaccination

AU - Schreiber, Taylor H.

AU - Deyev, Vadim V.

AU - Rosenblatt, Joseph D

AU - Podack, Eckhard R.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Established tumors suppress antitumor immune responses and induce tolerance by incompletely characterized mechanisms, and this phenomenon is an important barrier to tumor immunotherapy. Single vaccination with tumor cells expressing gp96-Ig stimulates robust expansion of tumor-specific CTLs in tumor-naive mice and this expansion is inhibited by established tumors. Interestingly, frequent vaccinations restore antitumor immune responses in the presence of established tumors. Syngeneic EG7 tumor-bearing mice have heterogeneous responses to frequent vaccination with EG7-gp96-Ig, with 32% complete responders and 68% partial responders. Comparison of responders to nonresponders revealed aninverse correlation between tumor-specific CTL expansion in the peripheral blood and tumor size. To identify immune cells and molecules associated with effective anti-tumor immune responses, reverse transcription-PCR arrays were performed using cells isolated from the vaccination site. ELISAs, cellular phenotyping, and tumor immunohistochemistry were also performed comparing vaccine responders to nonresponders. These data show that up-regulation of T-bet, ROHyt, IFNY, CCL8> CXCL9, and CXCLlO at the vaccination site are associated with vaccine-induced antitumor immunity. These data correlate with increased CTL expansion in the peripheral blood of responders, increased infiltration of responder tumors by CD8+ cells and interleukin-17+ cells, and decreased infiltration of responder tumors by CDllb+Gr-1+ cells and FoxP3+ cells. Furthermore, serum ELISAs revealed a significant elevation of transforming growth factor-ß in nonresponders as compared with responders. Interestingly, CD8+ T cells isolated from responders and nonresponders have equivalent cytotoxic activity in vitro. Taken together, our data suggest that established tumors may escape immuno-surveillance by preventing clonal expansion of tumor-specific CTL without inducing anergy.

AB - Established tumors suppress antitumor immune responses and induce tolerance by incompletely characterized mechanisms, and this phenomenon is an important barrier to tumor immunotherapy. Single vaccination with tumor cells expressing gp96-Ig stimulates robust expansion of tumor-specific CTLs in tumor-naive mice and this expansion is inhibited by established tumors. Interestingly, frequent vaccinations restore antitumor immune responses in the presence of established tumors. Syngeneic EG7 tumor-bearing mice have heterogeneous responses to frequent vaccination with EG7-gp96-Ig, with 32% complete responders and 68% partial responders. Comparison of responders to nonresponders revealed aninverse correlation between tumor-specific CTL expansion in the peripheral blood and tumor size. To identify immune cells and molecules associated with effective anti-tumor immune responses, reverse transcription-PCR arrays were performed using cells isolated from the vaccination site. ELISAs, cellular phenotyping, and tumor immunohistochemistry were also performed comparing vaccine responders to nonresponders. These data show that up-regulation of T-bet, ROHyt, IFNY, CCL8> CXCL9, and CXCLlO at the vaccination site are associated with vaccine-induced antitumor immunity. These data correlate with increased CTL expansion in the peripheral blood of responders, increased infiltration of responder tumors by CD8+ cells and interleukin-17+ cells, and decreased infiltration of responder tumors by CDllb+Gr-1+ cells and FoxP3+ cells. Furthermore, serum ELISAs revealed a significant elevation of transforming growth factor-ß in nonresponders as compared with responders. Interestingly, CD8+ T cells isolated from responders and nonresponders have equivalent cytotoxic activity in vitro. Taken together, our data suggest that established tumors may escape immuno-surveillance by preventing clonal expansion of tumor-specific CTL without inducing anergy.

UR - http://www.scopus.com/inward/record.url?scp=62449170994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449170994&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-3706

DO - 10.1158/0008-5472.CAN-08-3706

M3 - Article

C2 - 19223534

AN - SCOPUS:62449170994

VL - 69

SP - 2026

EP - 2033

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -